Department of Cardiology, Alfred Health, Melbourne, Australia.
Department of Cardiology, Alfred Health, Melbourne, Australia; Heart Failure Research Group, Baker Heart and Diabetes Institute, Melbourne, Australia.
Am J Cardiol. 2020 Dec 15;137:77-82. doi: 10.1016/j.amjcard.2020.09.039. Epub 2020 Oct 2.
Transcatheter aortic valve implantation (TAVI) is emerging as the default strategy for older patients with severe, symptomatic, and trileaflet aortic stenosis. Increased body-mass index (BMI) is associated with a protective effect in patients undergoing percutaneous coronary intervention. We assessed whether elevated BMI was associated with a similar association in TAVI. We evaluated prospectively collected data from 634 patients who underwent TAVI at 2 centers from August 2008 to April 2019. Patients were stratified as normal weight (BMI 18.5 to 24.9 kg/m, n = 214), overweight (25 to 29.9 kg/m, n = 234), and obese (>30 kg/m, n = 185). Outcomes were reported according to VARC-2 criteria. Mortality was assessed using Cox proportional hazards regression analysis (median follow-up 2 years). Kaplan-Meier analysis was used to estimate cumulative mortality. Baseline differences were seen in age (85 vs 84 vs 82, p <0.001), STS-PROM score (4.3 vs 3.4 vs 3.6, p <0.001), sex (50% vs 36% vs 55% female, p <0.001), clinical frailty score (p = 0.02), diabetes (21% vs 29% vs 40%, p <0.001), and presence of chronic obstructive pulmonary disease (COPD) (13% vs 13% vs 23%, p = 0.009). On multivariable analysis there was no mortality difference between normal and obese patients (hazard ratio [HR] 0.70, confidence interval [CI] 0.46 to 1.1 p = 0.11), however overweight patients had significantly lower mortality (HR 0.56 CI 0.38 to 0.85, p = 0.006). Variables independently associated with increased mortality were increasing age, male sex, COPD, previous balloon valvuloplasty, and higher STS-PROM. In conclusion, overweight patients have lower long-term mortality when compared with normal weight and obese patients undergoing TAVI.
经导管主动脉瓣植入术(TAVI)正在成为严重、有症状、三叶式主动脉瓣狭窄老年患者的默认治疗策略。身体质量指数(BMI)升高与经皮冠状动脉介入治疗患者的保护作用有关。我们评估了升高的 BMI 是否与 TAVI 中类似的关联有关。我们前瞻性地评估了 2008 年 8 月至 2019 年 4 月在 2 个中心接受 TAVI 的 634 名患者的数据。患者分为正常体重(BMI 18.5 至 24.9kg/m,n=214)、超重(25 至 29.9kg/m,n=234)和肥胖(>30kg/m,n=185)。根据 VARC-2 标准报告结局。使用 Cox 比例风险回归分析评估死亡率(中位随访 2 年)。Kaplan-Meier 分析用于估计累积死亡率。年龄(85 岁 vs 84 岁 vs 82 岁,p<0.001)、STS-PROM 评分(4.3 分 vs 3.4 分 vs 3.6 分,p<0.001)、性别(50% vs 36% vs 55%女性,p<0.001)、临床虚弱评分(p=0.02)、糖尿病(21% vs 29% vs 40%,p<0.001)和慢性阻塞性肺疾病(COPD)的存在(13% vs 13% vs 23%,p=0.009)方面存在基线差异。多变量分析显示,正常体重和肥胖患者之间的死亡率无差异(风险比[HR]0.70,95%置信区间[CI]0.46 至 1.1,p=0.11),但超重患者的死亡率显著降低(HR 0.56,95%CI 0.38 至 0.85,p=0.006)。与死亡率增加相关的独立变量是年龄增加、男性、COPD、既往球囊瓣膜成形术和较高的 STS-PROM。总之,与接受 TAVI 的正常体重和肥胖患者相比,超重患者的长期死亡率较低。